Clinical Trials Directory

Trials / Completed

CompletedNCT06382662

Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition

Assessment of the Effect of Metaxalone 640 mg (M640) on Truck Driving Ability and Cognition Compared to Tizanidine 8 mg: A Prospective, Single-blind, Within-subject Pilot Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Primus Pharmaceuticals · Industry
Sex
All
Age
20 Years – 70 Years
Healthy volunteers
Accepted

Summary

Every participant will receive active study drug and one (1 )comparator, in two (2) stages, one after the other. Each drug will be taken one (1) time after a high fat meal. Vital signs and discussion of medications, illness or injury are considered safety assessments and will be discussed at every visit. There will be ( four (4) visits.

Detailed description

Every participant will receive active study drug and one (1) comparator in two (2) stages, one after the other. Each drug will be taken one (1) time after a high fat meal. Vital signs and discussion of medications, illness or injury are considered safety assessments and will be discussed at every visit. The Screening Visit will be followed by the Baseline (Visit 1) 1-14 days later. At the Baseline Visit participants will be given written tests to measure thinking process. You will also be asked to take a computer driving simulation test. Visits 2 and 3 approximately one (1) week apart will be the dosing days after eating a high fat meal within 30 minutes. The testing from the Baseline Visit will be repeated at four (4) hours and 1.5 hours after dosing with comparator drug. The End of Study safety visit will take place two (2) weeks later. Participants will be given discharge instructions.

Conditions

Interventions

TypeNameDescription
DRUGmetaxalone m640A single dose of micronize metaxalone 640 mg
DRUGtizanidineA single dose of tizanidine 8 mg

Timeline

Start date
2024-04-29
Primary completion
2024-12-30
Completion
2025-03-06
First posted
2024-04-24
Last updated
2025-08-22

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06382662. Inclusion in this directory is not an endorsement.